Why and How Drugs Fail

Patil, Dada; Patwardhan, Bhushan; Kumbhare, Kalyani

doi:10.1016/b978-0-12-801814-9.00002-7

Cited by 3 publications

(3 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…† Hence, thalidomide may have a unique mechanism of action, acting as a general 'chaotic disorganiser' of embryonic DNA expression, thereby frustrating attempts to uncover a single and discrete mechanism of action but may help to explain why so many different mechanistic proposals have been forwarded. 55,68 A recent comprehensive review, whilst commenting upon the spectrum of disorders that thalidomide may induce within individuals, remarked, 'how and why the drug caused such a range and variability in damage remains unclear, but likely includes individual differences in metabolism and clearance of the drug, as well [as] genetic and environmental factors'. 55 This sums up the frustratingly ambivalent position that still exists over half a century later.…”

Section: Discussionmentioning

confidence: 99%

Thalidomide-type teratogenicity: structure–activity relationships for congeners

Smith

Mitchell

2018

Toxicology Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Thalidomide-type teratogenicity: structure–activity relationships for congeners

Smith

Mitchell

2018

Toxicology Research

View full text Add to dashboard Cite

show abstract

“…Moreover, the water solubility of Cel-CMCS was significantly higher than the natural celastrol. In addition, the in vitro stability analysis demonstrated that Cel-CMCS had controlled release properties for celastrol in both PBS (pH 7.4) and SIF (simulated intestinal fluid, pH 7.5) [296].…”

Section: Polymer Conjugatementioning

confidence: 97%

“…The release of the medication that is linked to another molecule depends on certain conditions, like alterations in pH, the presence of enzymes, or the susceptibility of specific diseased organs or tissues. In such situations, the linker assumes a crucial role [296].…”

Section: Polymer Conjugatementioning

confidence: 99%

Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges

Ashour,

Mabrouk,

Aboelnasr

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Obesity has reached an epidemic proportion in the last thirty years, and it is recognized as a major health issue in modern society now with the possibility of serious social and economic consequences. By the year 2030, nearly 60% of the global population may be obese or overweight, which emphasizes a need for novel obesity treatments. Various traditional approaches, such as pharmacotherapy and bariatric surgery, have been utilized in clinical settings to treat obesity. However, these methods frequently show the possibility of side effects while remaining ineffective. There is, therefore, an urgent need for alternative obesity treatments with improved efficacy and specificity. Polymeric materials and chemical strategies are employed in emerging drug delivery systems (DDSs) to enhance therapy effectiveness and specificity by stabilizing and controlling the release of active molecules such as natural ingredients. Designing DDSs is currently a top priority research objective with an eye towards creating obesity treatment approaches. In reality, the most recent trends in the literature demonstrate that there are not enough in-depth reviews that emphasize the current knowledge based on the creation and design of DDSs for obesity treatment. It is also observed in the existing literature that a complex interplay of different physical and chemical parameters must be considered carefully to determine the effectiveness of the DDSs, including microneedles, for obesity treatment. Additionally, it is observed that these properties depend on how the DDS is synthesized. Although many studies are at the animal-study stage, the use of more advanced DDS techniques would significantly enhance the development of safe and efficient treatment approaches for obese people in the future. Considering these, this review provides an overview of the current anti-obesity treatment approaches as well as the conventional anti-obesity therapeutics. The article aims to conduct an in-depth discussion on the current trends in obesity treatment approaches. Filling in this knowledge gap will lead to a greater understanding of the safest ways to manage obesity.

show abstract

From Selenium to Selenoproteins and their Role - Minireview

CATIANIS

Vîrgolici

Dogaru

et al. 2020

Acta Medica Transilvanica

View full text Add to dashboard Cite

Selenium (SE) is an essential micronutrient fulfilling a number of biological roles, being integrated as selenocysteine in the primary structure of certain selenoproteins. The Selenocysteine is synthesized and inserted into proteins during the translational process of the RNAm by a mechanism which involves converting a stop codon for certain proteins into a meaningful codon. Only 25 genes encoding selenocysteine-incorporating proteins have been identified in the human genome. The selenoprotein families including glutathione peroxidase, iodothyronine deiodinase and thioredoxin reductases are known as enzymes engaged in redox processes. The selenoprotein P (SEPP1) is a hepatokine produced by the liver, an extracellular glycoprotein, which is not part of these families. The purpose of this Article is to present the form of distribution of selenium and its physiological role in the body.

show abstract

Why and How Drugs Fail

Cited by 3 publications

References 118 publications

Thalidomide-type teratogenicity: structure–activity relationships for congeners

Thalidomide-type teratogenicity: structure–activity relationships for congeners

Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges

From Selenium to Selenoproteins and their Role - Minireview

Contact Info

Product

Resources

About